COMBINATION OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CORONAVIRUS DISEASES

A method of treatment for an individual infected with COVID-19 which comprises: - providing a first compound and a second compound, individually selected from the group consisting of: Epidermal Growth Factor Receptor (EGFR) Inhibitors; Serine Threonine Kinase Inhibitors; Vascular Endothelial Growth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HNIK, PETER, CORMIER, STEPHANIA, ADER, ALLAN, CHO, TIFFANY, WASAN, KISHOR M, BRYLINSKI, MICHAL, ABRAMOV, JULIA, BESS, ADAM, GOULD, JANET, JELESIJEVI, TOMISLAV, GRIGGS, NICHOLAS, MUKHOPADHYAY, SUPRATIK, GALLIANO, CHRIS, BERGLIND, FREJ KNUT GOSTA
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A method of treatment for an individual infected with COVID-19 which comprises: - providing a first compound and a second compound, individually selected from the group consisting of: Epidermal Growth Factor Receptor (EGFR) Inhibitors; Serine Threonine Kinase Inhibitors; Vascular Endothelial Growth Factor (VEGF) inhibitors; and STAT3 Inhibitors, and - administering to said individual a sufficient amount of said first compound and a sufficient amount of said second compound to produce a therapeutic effect against COVID-19, wherein said first compound and said compound are not from the same group and are not the same compound.